Neuren is essentially two very separate businesses: a Daybue royalty and future milestone business and the 2591 wonder drug business, with $300m-odd to fund its progress.
Acadia would be interested in acquiring both businesses, but most other pharmas would just want the 2591 wonder drug business.
so, I wonder if Neuren is exploring selling their Daybue asset to Acadia, thereby making the 2591 asset more attractive to other pharmas?
I also suspect if Neuren sold their Daybue side of business to Acadia for a fair price, the market would realise how undervalued the 2591 drug plus cash side of business was.
NEU Price at posting:
$10.30 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)